# A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.

> **NCT02839135** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 128 (actual)

## Conditions studied

- Motion Sickness

## Interventions

- **DRUG:** Reformulated scopolamine patch
- **DRUG:** Marketed scopolamine patch

## Key facts

- **NCT ID:** NCT02839135
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-13
- **Primary completion:** 2016-08-01
- **Final completion:** 2016-08-10
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2018-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02839135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02839135, "A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02839135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*